Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential for aromatase inhibition in breast cancer prevention.
Lønning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Schlichting E, Geisler J. Lønning PE, et al. Among authors: schlichting e. Clin Cancer Res. 2001 Dec;7(12 Suppl):4423s-4428s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916235 Review.
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Lønning PE, et al. Among authors: schlichting e. J Clin Oncol. 2005 Aug 1;23(22):5126-37. doi: 10.1200/JCO.2005.07.097. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983390 Clinical Trial.
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Geisler J, et al. Among authors: schlichting e. Eur J Cancer. 2006 Nov;42(17):2968-75. doi: 10.1016/j.ejca.2006.07.005. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16963261 Clinical Trial.
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: schlichting e. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PLoS One. 2011. PMID: 21556366 Free PMC article. Clinical Trial.
rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY, Choi JY, Couch FJ, Cox A, Cross SS, Cuk K, Czene K, Dörk T, Dos-Santos-Silva I, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hamann U, Hart SN, Hartman M, Hatse S, Hopper JL, Ito H, Jakubowska A, Kabisch M, Kang D, Kosma VM, Kristensen VN, Le Marchand L, Lee E, Li J, Lophatananon A, Jan Lubinski, Mannermaa A, Matsuo K, Milne RL; NBCS Collaborators; Neuhausen SL, Nevanlinna H, Orr N, Perez JI, Peto J, Putti TC, Pylkäs K, Radice P, Sangrajrang S, Sawyer EJ, Schmidt MK, Schneeweiss A, Shen CY, Shrubsole MJ, Shu XO, Simard J, Southey MC, Swerdlow A, Teo SH, Tessier DC, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tseng CC, Vachon C, Winqvist R, Wu AH, Yannoukakos D, Zheng W, Hall P, Dunning AM, Easton DF, Hooning MJ, van den Ouweland AM, Martens JW, Hollestelle A. Liu J, et al. Sci Rep. 2016 Nov 15;6:36874. doi: 10.1038/srep36874. Sci Rep. 2016. PMID: 27845421 Free PMC article.
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC. Aure MR, et al. Among authors: schlichting e. Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y. Breast Cancer Res. 2017. PMID: 28356166 Free PMC article.
DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC); Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN. Fleischer T, et al. Among authors: schlichting e. Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x. Nat Commun. 2017. PMID: 29123100 Free PMC article.
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B. Borgen E, et al. Among authors: schlichting e. Breast Cancer Res. 2018 Oct 16;20(1):120. doi: 10.1186/s13058-018-1049-0. Breast Cancer Res. 2018. PMID: 30322396 Free PMC article.
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study.
Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, Rosenlund AF, Sigstad E, Grøholt KK, Mæhle L, Engebretsen LF, Jørgensen LH, Varhaug JE, Bjøro T. Opsahl EM, et al. Among authors: schlichting e. Eur Thyroid J. 2019 Jan;8(1):31-40. doi: 10.1159/000493977. Epub 2018 Nov 8. Eur Thyroid J. 2019. PMID: 30800639 Free PMC article.
164 results